减少基因毒性测试对于含有明确特征修改的非编码寡核酸基疗法是可能的:欧洲监管视角
Clara Stock1, Britt Duijndam1, Christine L E Siezen1
1Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
Nucleic acid therapeutics
|March 13, 2026
概括
缺乏针对基于寡核酸的治疗药物 (ONT) 基因毒性测试的监管指导. 监管机构接受减少对ONT的测试,如果证明了足够的类经验,特别是对于已建立的化学修改.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 监管科学 监管科学
背景情况:
- 目前缺乏协调的监管指导,用于评估基于寡核酸的治疗药物的基因毒性潜力.
- 偏离标准基因毒性测试电池的具体情况尚未确立.
研究的目的:
- 分析获得欧洲科学建议的非编码ONT的基因毒性测试策略和理由.
- 通过检查申请人的立场和欧盟监管意见,确定基因毒性评估的关键考虑因素.
主要方法:
- 对91个非编码ONT的基因毒性测试数据的回顾性分析.
- 审查欧洲科学建议文档 (2004-2024年).
- 审查申请人的提交和欧盟监管反.
主要成果:
- 大多数ONT使用标准的基因毒性测试电池,但对10种产品提出了减少测试策略.
- 欧盟监管机构允许偏离标准电池,当有实质性的证据存在类经验时.
- 良好的特征修改 (例如,酸,2'-甲基乙烯,2'-甲基乙烯) 支持减少测试,使标准电池在这些情况下变得多余.
结论:
- 欧盟监管机构接受基于已证明的类经验对ONT进行降低基因毒性测试.
- 在即将发布的ICH S13指南中,明确定义"对类经验有足够的证据"对于统一的减少测试至关重要.
- 增加行业数据共享将促进对非编码ONT基因毒性评估的协调方法.
相关概念视频
Mutagenicity and Carcinogenicity
2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
In-vitro Mutagenesis
17.5K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.5K
Pharmacogenomics: Identification of New Drug Targets
61
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61


